Last checked at 22 Feb 2010 12:41
| For Immediate Release | 22 February 2010 |
ALLIANCE PHARMA PLC
| TR - 1: | NOTIFICATION OF MAJOR INTERESTS IN SHARES |
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | ALLIANCE PHARMA PLC (ISIN: GB0031030819) | |||
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||||
| An acquisition or disposal of voting rights |
| |||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
| |||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
| |||
| An event changing the breakdown of voting rights |
| |||
| Other (please specify): | Changes to disclosure requirements | X | ||
| 3. Full name of person(s) subject to the notification obligation: iii | NIGEL WILLIAM WRAY | |||
| 4. Full name of shareholder(s) (if different from 3.):iv | PERSHING NOMINEES LIMITED SMITH & WILLIAMSON NOMINEES LIMITED ROY NOMINEES LIMITED | |||
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | 22 FEBRUARY 2010 | |||
| 6. Date on which issuer notified: | 22 FEBRUARY 2010 | |||
| 7. Threshold(s) that is/are crossed or reached: vi, vii | 10% | |||
| 8. Notified details: | |||||||||||||||
| A: Voting rights attached to shares viii, ix | |||||||||||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||||||||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||||||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||||||
| ORDINARY SHARES GB0031030819 | 21,469,995 | 21,469,995 |
| 24,319,995 |
| 10.95% |
| ||||||||
|
| |||||||||||||||
| B: Qualifying Financial Instruments | |||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||||||||||
|
|
|
|
|
| |||||||||||
|
| |||||||||||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||||||||||
| Resulting situation after the triggering transaction | |||||||||||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||||||||||
|
|
|
|
|
| Nominal | Delta | |||||||||
|
|
| ||||||||||||||
|
| |||||||||||||||
| Total (A+B+C) | |||||||||||||||
| Number of voting rights | Percentage of voting rights | ||||||||||||||
| 24,319,995 | 10.95% | ||||||||||||||
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | ||
| Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees Pershing Nominees Limited 8,705,407 Smith & Williamson Nominees Limited 50,000 ROY NOMINEES LIMITED - 15,564,588 | ||
|
| ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | N/A | |
| 11. Number of voting rights proxy holder will cease to hold: | N/A | |
| 12. Date on which proxy holder will cease to hold voting rights: | N/A | |
|
| ||
| 13. Additional information: | N/A | |
| 14. Contact name: | Nigel Wray | |
| 15. Contact telephone number: | 020 7647 7647 | |